Identification of tropomyosin, paramyosin and apolipophorin/vitellogenin as three major allergens of the sheep scab mite, Psoroptes ovis
SUMMARY Analysis by one‐dimensional (1‐D) SDS‐PAGE/Western blotting of whole mite extract (larval and adult stages) with sheep sera taken 0–84 days after infection with the sheep scab mite, Psoroptes ovis revealed a progressive IgE antibody response, with a dominant high molecular weight allergen (M...
Saved in:
Published in | Parasite immunology Vol. 26; no. 8‐9; pp. 335 - 342 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Science Ltd
01.08.2004
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | SUMMARY
Analysis by one‐dimensional (1‐D) SDS‐PAGE/Western blotting of whole mite extract (larval and adult stages) with sheep sera taken 0–84 days after infection with the sheep scab mite, Psoroptes ovis revealed a progressive IgE antibody response, with a dominant high molecular weight allergen (MW 180 kDa) detected early during infection. Further analysis by two‐dimensional (2‐D) SDS‐PAGE/Western blotting with post‐infection sera, revealed a more complex picture with numerous (> 20) IgE reactive spots. Trypsin digest and Maldi‐ToF analyses of these spots identified two house dust mite allergen homologues, namely tropomyosin (Der p 10) and paramyosin (Der p 11), and analysis of a third spot indicated an apolipoprotein‐like IgE reactive protein (Der p 14). Further 1‐D and 2‐D SDS/Western blotting, with specific antibodies to the house dust mite allergens Der p 10, 11, and to the IgE reactive peptide of the high molecular weight house dust mite allergen, Der p 14 (vitellogenin/apolipophorin), provided firm evidence for the presence of these three allergens in extracts of the Psoroptes mite. These studies show for the first time that homologues of the house dust mite 10, 11 and 14 group allergens are represented as immunodominant allergens of the sheep scab mite, and may represent important vaccine candidates. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 0141-9838 1365-3024 |
DOI: | 10.1111/j.0141-9838.2004.00717.x |